## (19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 9 September 2005 (09.09.2005)

**PCT** 

(10) International Publication Number WO 2005/082422 A1

A61K 48/00, (51) International Patent Classification<sup>7</sup>: 38/17, A61P 35/00

(21) International Application Number:

PCT/US2005/006108

(22) International Filing Date: 24 February 2005 (24.02.2005)

(25) Filing Language:

**English** 

(26) Publication Language:

**English** 

(30) Priority Data:

60/547,145

24 February 2004 (24.02.2004) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US

60/547,145 (CON)

Filed on

24 February 2004 (24.02.2004)

- (71) Applicant (for all designated States except US): INTRO-GEN THERAPEUTICS, INC. [US/US]; 301 Congress Avenue, Suite 1850, Austin, TX 78701 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MENANDER, Kerstin [--/US]. SOBOL, Robert [--/US].
- (74) Agent: HIGHLANDER, Steven, L.; Fulbright & Ja-TX 78701 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidworski, LLP, 600 Congress Avenue, Suite 2400, Austin, ance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION OF AD-P53 AND CHEMOTHERAPY FOR THE TREATMENT OF TUMOURS

(57) Abstract: The present invention relates to the use of p53 gene therapy to treat recurrent cancers in combination with a radio- or chemotherapy. Patients with recurring cancers are treated with a p53 expression construct followed by subsequent radio- or chemotherapy treatment.. Viral and non-viral delivery systems, as well as various radio- and chemotherapy regimens are disclosed.